Gefitinib and a Ventriculo-peritoneal Shunt to Manage Carcinomatous Meningitis from Non-small-cell Lung Cancer: Report of Two Cases

Overview

Journal Surg Today

Specialty General Surgery

Date 2009 Jun 30

PMID 19562448

Citations 5

Authors

Tetsuya So

Masaaki Inoue

Yasuhiro Chikaishi

Naohiro Nose

Kenji Sugio

Kosei Yasumoto

Affiliations

Soon will be listed here.

Abstract

The prognosis of patients with carcinomatous meningitis from non-small-cell lung cancer (NSCLC) remains poor, and the available treatment options for the lung cancer do not relieve the severe symptoms of this sequela. We report the successful treatment of two cases of carcinomatous meningitis caused by NSCLC, using gefitinib and a ventriculo-peritoneal (V-P) shunt. The first patient was a 43-year-old woman with pT1N0M0 adenocarcinoma. Multiple brain and vertebral metastases were found 13 months after surgery. She had undergone gamma-knife radiosurgery for the brain metastases, radiotherapy for the vertebral metastases, and two regimens of systemic chemotherapy, before carcinomatous meningitis was diagnosed. She was given gefitinib, and then a V-P shunt was placed. She continued to take gefitinib and was free of subjected symptoms for 5 months until she died. The second patient was a 64-year-old woman with cT4N0M0 adenocarcinoma. After local chemotherapy using cisplatin and OK-432 for carcinomatosis pleuritis and two regimens of systemic chemotherapy, carcinomatous meningitis was detected. A V-P shunt was placed, and she was sequentially given gefitinib. At her 15-month follow-up, she was free of symptoms of carcinomatous meningitis. No adverse effects or shunt problems were detected in either patient. This therapeutic modality may liberate carcinomatous meningitis patients with severe symptoms from hospitalization and improve their quality of life.

Citing Articles

Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss.

Bian D, Lazaratos A, Maritan S, Quaiattini A, Zeng Z, Zhu Z Heliyon. 2024; 10(9):e29668.

PMID: 38698967 PMC: 11064091. DOI: 10.1016/j.heliyon.2024.e29668.

Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.

Yan W, Liu Y, Li J, Han A, Kong L, Yu J Radiat Oncol. 2019; 14(1):168.

PMID: 31521171 PMC: 6744654. DOI: 10.1186/s13014-019-1376-z.

Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation.

Morichika D, Kubo T, Gotoda H, Tamura T, Ohashi K, Hotta K Onco Targets Ther. 2016; 9:1753-8.

PMID: 27042125 PMC: 4809332. DOI: 10.2147/OTT.S95721.

[Diagnosis and Treatment of Leptomeningeal Metastasis in Non-small Cell Lung Cancer].

Xu Y, Li L, Wang M Zhongguo Fei Ai Za Zhi. 2015; 18(10):626-32.

PMID: 26483335 PMC: 6000085. DOI: 10.3779/j.issn.1009-3419.2015.10.05.

Carcinomatous meningitis: Leptomeningeal metastases in solid tumors.

Le Rhun E, Taillibert S, Chamberlain M Surg Neurol Int. 2013; 4(Suppl 4):S265-88.

PMID: 23717798 PMC: 3656567. DOI: 10.4103/2152-7806.111304.

References

Sudo J, Honmura Y, Kurimoto F, Komagata H, Sakai H, Yoneda S . [Meningeal carcinomatosis in patients with lung cancer]. Nihon Kokyuki Gakkai Zasshi. 2006; 44(11):795-9. View

Kris M, Natale R, Herbst R, Lynch Jr T, Prager D, Belani C . Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290(16):2149-58. DOI: 10.1001/jama.290.16.2149. View

Grossman S, Krabak M . Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999; 25(2):103-19. DOI: 10.1053/ctrv.1999.0119. View

Wasserstrom W, Glass J, Posner J . Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982; 49(4):759-72. DOI: 10.1002/1097-0142(19820215)49:4<759::aid-cncr2820490427>3.0.co;2-7. View

Mountain C, Dresler C . Regional lymph node classification for lung cancer staging. Chest. 1997; 111(6):1718-23. DOI: 10.1378/chest.111.6.1718. View

Arteaga C, Johnson D . Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol. 2001; 13(6):491-8. DOI: 10.1097/00001622-200111000-00012. View

Sakai M, Ishikawa S, Ito H, Ozawa Y, Yamamoto T, Onizuka M . Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib. Int J Clin Oncol. 2006; 11(3):243-5. DOI: 10.1007/s10147-005-0558-x. View

Hashimoto N, Imaizumi K, Honda T, Kawabe T, Nagasaka T, Shimokata K . Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. Lung Cancer. 2006; 53(3):387-90. DOI: 10.1016/j.lungcan.2006.05.016. View

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

10.

Janne P, Gurubhagavatula S, Yeap B, Lucca J, Ostler P, Skarin A . Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer. 2004; 44(2):221-30. DOI: 10.1016/j.lungcan.2003.12.014. View

11.

Grossman S, Finkelstein D, Ruckdeschel J, Trump D, Moynihan T, Ettinger D . Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol. 1993; 11(3):561-9. DOI: 10.1200/JCO.1993.11.3.561. View

12.

Katz A, Zalewski P . Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib. Br J Cancer. 2003; 89 Suppl 2:S15-8. PMC: 2750244. DOI: 10.1038/sj.bjc.6601478. View

13.

Hanagiri T, Sugio K, Uramoto H, So T, Ichiki Y, Sugaya M . Gender difference as a prognostic factor in patients undergoing resection of non-small cell lung cancer. Surg Today. 2007; 37(7):546-51. DOI: 10.1007/s00595-006-3453-9. View

14.

Kim M, Lee K, Lee J, Choi J, Hyun M . Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer. 2005; 50(2):265-9. DOI: 10.1016/j.lungcan.2005.05.022. View

15.

Haimovic I, Sharer L, HYMAN R, Beresford H . Metastasis of intracranial germinoma through a ventriculoperitoneal shunt. Cancer. 1981; 48(4):1033-6. DOI: 10.1002/1097-0142(19810815)48:4<1033::aid-cncr2820480430>3.0.co;2-r. View

16.

Miller V, Kris M, Shah N, Patel J, Azzoli C, Gomez J . Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004; 22(6):1103-9. DOI: 10.1200/JCO.2004.08.158. View

17.

Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins S . Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005; 65(8):3328-35. DOI: 10.1158/0008-5472.CAN-04-3547. View

18.

King P . The peritoneal complications of ventriculo-peritoneal shunts. Aust N Z J Surg. 1976; 46(4):372-7. DOI: 10.1111/j.1445-2197.1976.tb03251.x. View

19.

Omuro A, Lallana E, Bilsky M, DeAngelis L . Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology. 2005; 64(9):1625-7. DOI: 10.1212/01.WNL.0000160396.69050.DC. View

20.

Mehta M, Rodrigus P, Terhaard C, Rao A, Suh J, Roa W . Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003; 21(13):2529-36. DOI: 10.1200/JCO.2003.12.122. View